Chronic Lymphocytic Leukemia News and Research

RSS
Chronic Lymphocytic Leukemia (CLL) is the most common form of leukemia in adults. According to the American Cancer Society, approximately 8,000 patients will be diagnosed this year. More than 60,000 people in the U.S. currently have CLL. The disease arises in lymphocytes, a type of white blood cell that normally produces antibodies and serves important immune functions.
Celgene announces regulatory submissions for blood cancer therapies REVLIMID and ISTODAX

Celgene announces regulatory submissions for blood cancer therapies REVLIMID and ISTODAX

Clinical, preclinical results of ISF35 in CLL patients presented at ASH 2010

Clinical, preclinical results of ISF35 in CLL patients presented at ASH 2010

p53 activation offers a novel strategy for cancer therapy

p53 activation offers a novel strategy for cancer therapy

John Theurer Cancer Center presents research findings at ASH meeting

John Theurer Cancer Center presents research findings at ASH meeting

Micromet announces presentation of updated results from MT103 Phase 2 trial in MRD positive ALL patients

Micromet announces presentation of updated results from MT103 Phase 2 trial in MRD positive ALL patients

Promising Phase 2 data of perifosine in CLL and HL presented at 52nd ASH

Promising Phase 2 data of perifosine in CLL and HL presented at 52nd ASH

Reason behind recurrence of CLL in lymph nodes and bone marrow after chemotherapy

Reason behind recurrence of CLL in lymph nodes and bone marrow after chemotherapy

Encouraging data from perifosine Phase 2 studies in advanced leukemia, Hodgkin's lymphoma

Encouraging data from perifosine Phase 2 studies in advanced leukemia, Hodgkin's lymphoma

No overall cancer risk in people who donate stem cells

No overall cancer risk in people who donate stem cells

Preclinical study results for Syk, JAK inhibitor program presented at ASH 2010

Preclinical study results for Syk, JAK inhibitor program presented at ASH 2010

BioCryst reports Phase 2 trial data of forodesine in patients with CLL

BioCryst reports Phase 2 trial data of forodesine in patients with CLL

Alexion Pharmaceuticals reports interim results from phase 1 trial on samalizumab antibody

Alexion Pharmaceuticals reports interim results from phase 1 trial on samalizumab antibody

Clinical data of PCI-32765 in patients with CLL presented at ASH Annual Meeting

Clinical data of PCI-32765 in patients with CLL presented at ASH Annual Meeting

New studies answer questions related to stem cell transplant procedures in treating hematologic malignancies

New studies answer questions related to stem cell transplant procedures in treating hematologic malignancies

New drug for non-Hodgkin’s lymphoma shows promise

New drug for non-Hodgkin’s lymphoma shows promise

Clinical studies participated by three investigators to be presented at ASH Annual Meeting and Exposition

Clinical studies participated by three investigators to be presented at ASH Annual Meeting and Exposition

Merck to present multiple clinical studies of dinaciclib at ASH Annual Meeting

Merck to present multiple clinical studies of dinaciclib at ASH Annual Meeting

Xencor, MorphoSys initiate XmAb5574 Phase 1 study in CLL

Xencor, MorphoSys initiate XmAb5574 Phase 1 study in CLL

CytRx commences tamibarotene Phase 2b clinical trial in NSCLC

CytRx commences tamibarotene Phase 2b clinical trial in NSCLC

Calistoga to feature data on CAL-101 inhibitor for hematologic malignancies at ASH Annual Meeting

Calistoga to feature data on CAL-101 inhibitor for hematologic malignancies at ASH Annual Meeting

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.